ZRANB2 and breast cancer: The NTR protein SYF2 [279] was, together with the zinc finger RNA-binding splicing factor ZRANB2, identified as a putative therapeutic target in a small siRNA screen silencing 19 spliceosome proteins that were found overexpressed in doxorubicin-resistant breast cancer cells.